This finding is similar to Prado-Garcia et al., where 3–6% of MPE CD8+ and CD4+ T cells co-expressed PD-1+TIM-3+ or PD-1+LAG-3+ in lung cancer patients pre-treatment [38]. This evidence concerns the gene HAVCR2 and lung carcinoma.